Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs
- 1 May 2001
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 2 (5) , 278-289
- https://doi.org/10.1016/s1470-2045(00)00323-5
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Antiangiogenic Activity of the Cleaved Conformation of the Serpin AntithrombinScience, 1999
- Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularizationJournal of Clinical Investigation, 1999
- Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in MiceScience, 1999
- Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic modelsEuropean Journal Of Cancer, 1996
- Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluationEuropean Journal Of Cancer, 1996
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisPublished by Elsevier ,1996
- Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumoursNature, 1996
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESISThe Journal of Experimental Medicine, 1971